For the first time, scientists have developed a drug that works on both major aggregation-promoting 'hotspots' of the Tau protein in the brain -- a key driver of neurodegeneration. The drug ...

Holly Geyer, an addiction medicine specialist and the lead physician of the Mayo Clinic opioid stewardship program in Arizona, explains that in an effort to help combat opioid-related drug abuse ...

Harry Sumnall receives funding from public grant awarding bodies for alcohol and other drugs research, and fees from (international) not-for-profit organisations and government departments for ...

In my previous article, I discussed how AI is rapidly transforming the drug discovery process, significantly accelerating timelines and reducing costs. However, while AI's potential in this domain ...

Available antipsychotic treatments work by blocking dopamine receptors. The new drug, Cobenfy, takes a different approach. By Ellen Barry and Christina Jewett The Food and Drug Administration on ...

Patients in the study will continue to be followed for at least five years to monitor potential long-term side effects. For patients with hemophilia B, the current standard of care of ongoing ...

The synthetic version has been taken for more than 100 years and was initially released under the brand name Pitressin. The U.S. Food and Drug Administration (FDA) has licensed it under the brand name ...

Joseph Janes does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond ...

The smoking-cessation drugs on the market don’t work well for the majority of people, and they come with side effects and reputations that keep some smokers from ever trying them. Despite this ...